PRF With Topical Antibiotics or Antiseptics in Chronical Wounds Version 1.4

Inclusion Criteria: * Males and females aged over 18 who are able to give informed consent * Chronic venous ulcer with localized non-systemic soft-tissue infection diagnosed by senior infectious diseases specialist based on US FDA Guidance for Industry Chronic cutaneous ulcer and burn wounds June 2006: * slough and necrotic tissue * exsudate * smell * inflammation * presence of granulation tissue * pain * Wound size ≥ 5 cm2 and \< 200 cm2 Exclusion Criteria: * Non-treated diabetes mellitus, HbA1c \> 12 mg/dl * Non treated (orthopaedic shoe) diabetic foot syndrome * ABI \< 0,7 * Wound size 15 cm2 and \> 200 cm2 * CRP \> 5 mg/dl * Leucocytes \> 15.000 /μl * Infection of another site * Infection of the ulcer with a pathogen with inherent resistance to amikacin and teicoplanin * Known osteomyelitis * Known erysipelas * Known phlegmon * Complicated deep tissue infection not solely treatable with PRF plus antimicrobial therapy in the opinion of a senior infectious diseases specialist * Planned systemic antimicrobial therapy * Active viral hepatitis (A/B/C) or active HIV infection or active syphilis * Increased sensitivity to amikacin or teicoplanin, PHMB or macrogolol * Increased sensitivity to tramexanic acid or batroxobin * Presence of neoplastic growth in the ulcer * Thrombocytopenic patients (\<150.000 G/L) * Haemoglobin \< 95 g/L * Known pregnancy or lactation * Severe renal impairment (creatinine clearance \<30 ml/min) * History or clinical signs of impairment of the cochlea or vestibularis system * Neuromuscular diseases (i.e. Myasthenia gravis, Parkinson's disease) * Aminoglycoside treatment less than four weeks before inclusion * Other reasons opposing the study participation on the discretion of the investigators